Skip to main content

4 Result(s)

within Véronique Leblond Remove this filter Cancer Research Remove this filter

and

  1. No Access

    Article

    Circulating tumor cells in Waldenström macroglobulinemia

    Clémentine Boccon-Gibod, Elise Sourdeau, Pierre Morel, Elise Chapiro… in Leukemia (2024)

  2. No Access

    Article

    Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia

    Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled in...

    Rémi Letestu, Abdelmalek Dahmani, Marouane Boubaya, Lucile Baseggio… in Leukemia (2021)

  3. Article

    Open Access

    Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study

    GREEN (NCT01905943) is a nonrandomized, open-label, single-arm, phase 3b study investigating the safety and efficacy of obinutuzumab alone or in combination with chemotherapy in chronic lymphocytic leukemia (C...

    Francesc Bosch, Guy Cantin, Agostino Cortelezzi, Wolfgang Knauf, Mourad Tiab… in Leukemia (2020)

    Download PDF (604 KB) View Article

  4. No Access

    Chapter and Conference Paper

    Identification of Prognostic Factors in Post-Transplant Lymphoproliferative Disorders

    Organ transplantations can lead to post-transplant lymphoproliferative disorders (PT-LPDs) as a result of immunosuppressive therapy. PT-LPDs clearly differ from non-Hodgkin’s lymphomas occurring in immunocompe...

    Sylvain Choquet, Marie-France Mamzer Bruneel… in Immunosurveillance, Immunodeficiencies and… (2002)